文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

难治性心脏骤停体外心肺复苏(ECPR)的成本效果与生活质量分析

Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest.
PubMed 文献 · Resuscitation · 2019-03-26
一句话结论在澳大利亚悉尼两家ECMO中心,62例难治性心脏骤停ECPR患者人均费用75,165澳元,10年ICER为25,212澳元/QALY,作者认为ECPR具有成本效果。

该研究基于澳大利亚悉尼两家ECMO中心全部62例连续ECPR患者的费用数据,建立Markov模型评估费用、生活质量与生存结局,计算每QALY费用与增量成本效果比(ICER)。患者平均年龄51.9±13.6岁,38例(61%)为院内心脏骤停(IHCA),25例(40%)存活至出院且脑功能分类(CPC)均为1或2。人均ECPR费用为75,165澳元(50,535欧元;±75,737澳元);10年估计每例平均增加3.0个QALY,ICER为25,212澳元(16,890欧元)/QALY,15年生存情景下增至4.0个QALY、ICER为18,829澳元(12,614欧元)/QALY。作者结论认为ECPR具有成本效果,与公认的成本效果阈值相比更有利。

要点

  • 62例连续ECPR患者中25例(40%)存活至出院,全部CPC为1或2,平均年龄51.9±13.6岁,38例(61%)为IHCA。
  • ECPR人均费用为75,165澳元(50,535欧元;±75,737澳元)。
  • 10年Markov模型估计ECPR每例平均增加3.0个QALY,ICER为25,212澳元(16,890欧元)/QALY。
  • 15年生存情景下估计每例增加4.0个QALY,ICER为18,829澳元(12,614欧元)/QALY。
  • 每QALY平均费用在OHCA与IHCA之间无显著差异。

适用人群与场景

  • 澳大利亚悉尼两家ECMO中心连续纳入的全部62例接受ECPR的难治性心脏骤停患者,平均年龄51.9±13.6岁,38例(61%)为院内心脏骤停(IHCA)。

研究设计与关键结果

  • 研究类型为基于两家ECMO中心全部ECPR患者费用数据的成本分析,并建立Markov模型评估费用、生活质量与生存结局,计算每QALY费用与ICER,并行概率敏感性分析(PSA)评估成本效果概率。
  • 共分析62例连续ECPR患者,平均年龄51.9±13.6岁,38例(61%)为IHCA。
  • 25例(40%)存活至出院,全部脑功能分类(CPC)为1或2。
  • 人均ECPR费用为75,165澳元(50,535欧元;±75,737澳元)。
  • 10年估计ECPR每例平均增加3.0个QALY,ICER为25,212澳元(16,890欧元)/QALY;15年生存情景下增至4.0个QALY、ICER为18,829澳元(12,614欧元)/QALY。
  • 每QALY平均费用在OHCA与IHCA之间无显著差异。

证据类型、等级与局限

  • 证据类型:基于两家ECMO中心全部ECPR患者费用数据的成本分析与Markov模型建模研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对难治性心脏骤停的ECMO支持具有成本效果,与公认的成本效果阈值相比更有利。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in refractory cardiac arrest (ECPR) has increased exponentially. ECPR is a resource intensive service and its cost effectiveness has yet to be demonstrated. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes of patients who have undergone ECPR.

METHODS: Using data on all extracorporeal cardiopulmonary resuscitation (ECPR) patients at two ECMO centres in Sydney, Australia; we completed a costing analysis of ECPR patients. A Markov model of cost, quality of life and survival outcomes was developed to examine cost per QALY estimates and incremental cost effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was completed to assess the probability of cost effectiveness for base case and variations.

RESULTS: Sixty-two consecutive ECPR patients were analysed; mean age of 51.9 ± 13.6 years, 38 (61%) were in hospital cardiac arrests (IHCA). Twenty-five patients (40%) survived to hospital discharge; all with a cerebral performance category (CPC) of 1 or 2. The mean cost per ECPR patient was AUD 75,165 (€50,535; ±AUD 75,737). Over 10 years ECPR was estimated to add a mean gain of 3.0 Quality Adjusted Life Years (QALYs) per patient with an incremental cost effectiveness ratio (ICER) of AUD 25,212 (€16,890) per QALY, increasing to 4.0 QALYs and an ICER of AUD 18,829 (€12,614) over a 15-year survival scenario. Mean cost per QALY did not differ significantly by OHCA or IHCA.

CONCLUSIONS: ECMO support for refractory cardiac arrests is cost effective and compares favourably to accepted cost effectiveness thresholds.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Dennis M, Zmudzki F, Burns B, et al. Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest. Resuscitation. 2019. PMID: 30922936. doi:10.1016/j.resuscitation.2019.03.021

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。